Xenetic Biosciences, Inc. (XBIO): Results of Operations and Financial Condition

Xenetic Biosciences (XBIO) agreed to acquire Santersus AG in an all-stock deal, pending shareholder approval. The combined company will rebrand as Santersus Bio, Inc. and trade under SNTS. The merger focuses on neutrophil extracellular traps (NETs) for treating various diseases, with four clinical programs planned. XBIO shares fell 40.98% to $2.52 on Wednesday, according to Benzinga Pro.

Xenetic Biosciences (XBIO) will merge with private Santersus AG in an all-stock deal, creating a Nasdaq-listed company focused on NET-targeting therapies. Existing XBIO shareholders will own 15% of the combined entity, named Santersus Bio (SNTS), while Santersus shareholders get 85%. The merger, expected to close in Q4 2026, combines four clinical programs, including two with FDA Breakthrough Device Designation. The combined company will be led by Santersus CEO James Ladtkow.

Xenetic Biosciences (NASDAQ:XBIO) reported Q2 2026 results for the quarter ended June 30. Royalty revenue rose about 12% to about $0.7M, while R&D fell about 16% to about $0.6M. G&A increased about 64% to about $1.1M, driving a net loss of about $0.9M. Cash was about $6.5M. The company cited ASCO preclinical/translational data and a PeriNess study approval.

J.B. Hunt Transport Services (JBHT) stock fell over 12% after CFO Brad Delco forecasted a 5-10% sequential decline in Q3 net earnings due to rising diesel costs and driver expenses. Several analysts, including those at Wells Fargo and Bank of America, cut price targets but maintained buy ratings. Jeff Kauffman of Citizens upgraded the stock to a buy with a $300 target, citing temporary cost pressures.

Millicom (TIGO) reported Q2 2026 revenue up 59.4% YoY to $2.18B, with EBITDA crossing $1B for the first time. However, net profit dropped 83.9% to $109M. The company raised its full-year equity free cash flow guidance to ~$1.1B and declared additional dividends. Organic revenue growth was only 4.3%, and capital spending increased significantly. Hedge fund ownership decreased, while short interest remained low.

APA Corp. reported Q2 adjusted production of 347,000 barrels of oil equivalent per day, exceeding guidance. It raised full-year US oil guidance to 123,000 barrels per day and increased its cost-savings target to $500 million. Free cash flow reached $738 million, with $189 million returned to shareholders. The company reduced net debt to $3.3 billion and expects to hit its $3 billion target in 2027. APA also announced acquisitions and exploration plans in Alaska, Uruguay, and Suriname, while noti